Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Andrew Krystal, MD (ucsf)
Headshot of Andrew Krystal
Andrew Krystal

Description

Summary

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in adult participants (ages ≥18 years) with idiopathic hypersomnia (IH).

Official Title

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) Followed by an Open-label Extension

Details

Approximately 248 participants are planned for randomization in the study. The study will consist of a Screening/Baseline Period (up to 28 days), a Double-blind Treatment Period (8 weeks), an optional Open-label Extension (OLE) Period (1 year), and 30 days of safety follow-up.

Keywords

Idiopathic Hypersomnia, pitolisant, HBS-301, excessive daytime sleepiness, sleep inertia, fatigue, Disorders of Excessive Somnolence, HBS-301 tablet

Eligibility

You can join if…

Open to people ages 18 years and up

  • Has a current documented diagnosis of IH per the International Classification of Sleep Disorders, Third Edition (ICSD-3) or Text Revision (ICSD-3-TR) criteria with confirmatory polysomnogram (PSG) with multiple sleep latency test (MSLT; and if applicable, a 24-hour PSG report or an actigraphy report with sleep log) on file that led to the diagnosis and was completed within the last 10 years.
  • Has EDS.
  • Has moderate to very severe symptoms of IH.
  • If taking a permitted chronic concomitant medication or supplement, including nonprohibited antidepressants or wake-promoting agents, must be on a stable dose for at least 3 months prior to Screening and agree to continue at that stable dose for the Double-blind Treatment Period of the study. As-needed use of any treatment that could affect daytime sleepiness (including but not limited to stimulants, modafinil, and armodafinil) used on an as-needed basis is not permitted.

You CAN'T join if...

  • Has hypersomnia due to another medical disorder.
  • Has a history of pitolisant use within 5 half-lives prior to Screening.
  • Has a primary diagnosis of psychiatric illness, including depression, that is not well controlled.
  • Has a history of moderate or severe hepatic impairment.
  • Has a body surface area (BSA)-corrected estimated glomerular filtration rate (eGFR) <60 mL/min.
  • Has a known history of long QT syndrome or any significant history of a serious abnormality of the electrocardiogram (ECG).

Locations

  • University of California San Francisco accepting new patients
    San Francisco California 94107 United States
  • Santa Monica Clinical Trials accepting new patients
    Santa Monica California 90404 United States
  • Stanford Center for Sleep Medicine accepting new patients
    Redwood City California 94063 United States

Lead Scientist at University of California Health

  • Andrew Krystal, MD (ucsf)
    Dr. Krystal is the Ray and Dagmar Dolby Distinguished Professor in the Departments of Psychiatry and Neurology, Vice-Chair for Research in the Department of Psychiatry, Director of the Dolby Family Center for Mood Disorders, Director of the UCSF Interventional Psychiatry Program and Director of the Clinical and Translational Sleep Research Laboratory.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Harmony Biosciences Management, Inc.
ID
NCT07500090
Phase
Phase 3 Idiopathic Hypersomnia Research Study
Study Type
Interventional
Participants
Expecting 248 study participants
Last Updated